Amgen (AMGN) Return on Capital Employed (2009 - 2026)
Amgen's quarterly Return on Capital Employed came in at 15.87% in Q1 2026, up 486.0% year-on-year from 2.71% in Q1 2025, and up 13.39% quarter-over-quarter from 14.0% in Q4 2025.
Amgen has reported Return on Capital Employed for 17 years, with the latest figure at 15.87% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 486.0% year-over-year to 15.87%; the trailing twelve-month figure through Mar 2026 stood at 15.87% (up 486.0% YoY), and the FY2025 full-year result was 13.82%, up 365.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 15.87%, up from 14.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.44% in Q3 2022, with the low at 8.79% in Q2 2024.
- Average Return on Capital Employed over 5 years is 13.55%, with a median of 12.9% recorded in 2025.
- Year-over-year, Return on Capital Employed soared 499 bps in 2022 and sank 917 bps in 2023.
- Tracing AMGN's Return on Capital Employed over 5 years: stood at 19.63% in 2022, then slumped by 47 bps to 10.47% in 2023, then rose by 2 bps to 10.63% in 2024, then jumped by 32 bps to 14.0% in 2025, then increased by 13 bps to 15.87% in 2026.
- The last three Return on Capital Employed figures came in at 15.87% (Q1 2026), 14.0% (Q4 2025), and 12.9% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.87% |
| Dec 31, 2025 | 14.00% |
| Sep 30, 2025 | 12.90% |
| Jun 30, 2025 | 12.02% |
| Mar 31, 2025 | 11.01% |
| Dec 31, 2024 | 10.63% |
| Sep 30, 2024 | 8.81% |
| Jun 30, 2024 | 8.79% |
| Mar 31, 2024 | 9.25% |
| Dec 31, 2023 | 10.47% |
| Sep 30, 2023 | 12.06% |
| Jun 30, 2023 | 13.12% |
| Mar 31, 2023 | 14.33% |
| Dec 31, 2022 | 19.63% |
| Sep 30, 2022 | 20.44% |
| Jun 30, 2022 | 20.07% |
| Mar 31, 2022 | 16.94% |
| Dec 31, 2021 | 15.01% |
| Sep 30, 2021 | 15.45% |
| Jun 30, 2021 | 15.93% |
| Mar 31, 2021 | 17.87% |
| Dec 31, 2020 | 17.53% |
| Sep 30, 2020 | 16.73% |
| Jun 30, 2020 | 17.42% |
| Mar 31, 2020 | 19.56% |
| Dec 31, 2019 | 20.68% |
| Sep 30, 2019 | 20.54% |
| Jun 30, 2019 | 19.30% |
| Mar 31, 2019 | 19.06% |
| Dec 31, 2018 | 19.22% |
| Sep 30, 2018 | 18.39% |
| Jun 30, 2018 | 17.59% |
| Mar 31, 2018 | 15.53% |
| Dec 31, 2017 | 14.02% |
| Sep 30, 2017 | 14.23% |
| Jun 30, 2017 | 14.53% |
| Mar 31, 2017 | 14.85% |
| Dec 31, 2016 | 14.69% |
| Sep 30, 2016 | 14.10% |
| Jun 30, 2016 | 14.20% |
| Mar 31, 2016 | 13.67% |
| Dec 31, 2015 | 13.45% |
| Sep 30, 2015 | 12.27% |
| Jun 30, 2015 | 11.11% |
| Mar 31, 2015 | 10.93% |
| Dec 31, 2014 | 9.85% |
| Sep 30, 2014 | 9.61% |
| Jun 30, 2014 | 10.17% |
| Mar 31, 2014 | 9.92% |
| Dec 31, 2013 | 10.94% |
| Sep 30, 2013 | 11.54% |
| Jun 30, 2013 | 11.62% |
| Mar 31, 2013 | 11.59% |
| Dec 31, 2012 | 11.95% |
| Mar 31, 2010 | 16.95% |
| Dec 31, 2009 | 15.12% |
| Sep 30, 2009 | 15.78% |